News Releases

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--

--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan--

--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories--

-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-

--ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--

-- First and Only Therapy Approved in Japan, Europe, and United States for This Difficult-To-Treat Condition --

--ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands--

--TPIP Generally Safe and Well Tolerated in Healthy Volunteers--

--Call Scheduled for Friday, February 19, 2021, at 8:30 a.m. ET--

--First Patient Dosed in Post-Marketing Program Intended to Support Full FDA Approval of ARIKAYCE and sNDA in Newly Diagnosed Patients--

--First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--